IMCIVREE (setmelanotide): Audience

IMCIVREE (setmelanotide) is a FDA-approved treatment designed for patients with rare neuroendocrine diseases, specifically targeting obesity and insatiable hunger. It is particularly indicated for patients as young as 2 years old with Bardet-Biedl syndrome.